Article Text

PDF
Molecular changes in the progression of Barrett’s oesophagus
  1. Edyta Zagorowicz1,
  2. Janusz Jankowski2,*
  1. 1Department of Gastroenterology, Institute of Oncology, Warsaw, Poland
  2. 2Department of Clinical Pharmacology, University of Oxford, Oxford, UK
  1. Correspondence to:
 Professor Janusz Jankowski
 Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford OX2 6HE, UK; janusz.jankowski{at}clinpharm.ox.ac.uk

Abstract

Barrett’s oesophagus is a frequent complication of gastro-oesophageal reflux disease predicting oesophageal adenocarcinoma. The majority of Barrett’s patients will not develop cancer, so that specific methods of identification of those at risk are required. Recent molecular studies have identified a selection of candidate biomarkers that need validation in prospective studies. They reflect various changes in cell behaviour during neoplastic progression. The ASPECT trial in the UK aims to establish whether chemoprevention with aspirin and a proton pump inhibitor will reduce adenocarcinoma development and mortality in patients with Barrett’s oesophagus. It will also validate biomarkers for progression and clinical response and further study disease pathogenesis.

  • APC, adenomatous polyposis coli
  • COX-2, cyclooxygenase-2
  • ECGF1, endothelial growth factor 1
  • GORD, gastro-oesophageal reflux disease
  • HGD, high grade dysplasia
  • hTERT, telomerase reverse transcriptase catalytic sub-unit
  • hTR, telomerase RNA
  • LGD, low grade dysplasia
  • LOH, loss of heterozygosity
  • NSAIDs, non-steroidal anti-inflammatory drugs
  • PPI, proton pump inhibitor
  • PCNA, proliferating cell nuclear antigen
  • PGE2, prostaglandin E2
  • SFRP, secreted frizzled-related proteins
  • SPARC, secreted protein, acidic, cysteine-rich
  • TRAP, telomerase repeat assay protocol
  • TSPAN, tetraspan1

Statistics from Altmetric.com

Footnotes

  • * Also Department of Gastroenterology, Institute of Oncology, Warsaw, Poland, and Digestive Diseases Centre, University Hospitals of Leicester, Leicester, UK

  • Funding: Cancer Research UK, University Hospitals of Leicester and Polish Foundation of Gastroenterology

  • Conflict of interest: none stated

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.